Jan 12, 2015, 13:00 PM by Michael Croft

Jan 12, 2015, 09:00 AM by Michael Croft

Jan 12, 2015, 00:00 AM by Michael Croft

BostonGlobe.com | These are boom times in biotechnology. Forty-one new drugs were approved for US sale in 2014, the highest tally in 18 years. A record 63 biotech startups went public, breaking the 1999 record of 52 initial public offerings. And the value of biopharma merger deals nearly tripled to $223 billion from a year earlier.

Jan 12, 2015, 00:00 AM by Michael Croft

CALIFORNIA, CA, UNITED STATES - Jan 12, 2015 - The report firstly introduced  Prokaryotic Expression Systems Market basic information including  Prokaryotic Expression Systems Market definition, classification, application and Market chain overview;  Prokaryotic Expression Systems  Market policy and plan,  Prokaryotic Expression Systems  product specification, manufacturing process, cost structure etc

Jan 12, 2015, 00:00 AM by Michael Croft

Boston Business Journal | The Cambridge biotech firm, known best for its drugs for multiple sclerosis, announced the acquisition of Convergence Pharmaceuticals.

Jan 12, 2015, 00:00 AM by Michael Croft

Bloomberg | 23andMe Inc., the genetic-testing startup backed by Google Inc., is sharing DNA data on about 650,000 individuals with Pfizer Inc., to help find new targets to treat disease and to design clinical trials.

Jan 12, 2015, 00:00 AM by Michael Croft

HARDERWIJK, THE NETHERLANDS - Jan 12, 2015 - Today GENALICE and Knome, Inc. USA jointly announced a strategic partnership to offer their products together as a turn-key solution for those using next-generation sequencing (NGS) data to interpret patients' genomes

Jan 9, 2015, 14:00 PM by Michael Croft

Jan 9, 2015, 00:00 AM by Michael Croft

NEW YORK, NY, UNITED STATES - Jan 9, 2015 - CAMBRIDGE, MA, and NEW YORK, NY (January 9, 2015) - Biogen Idec (NASDAQ: BIIB) and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches

Jan 8, 2015, 10:00 AM by Michael Croft

Forbes | 2014 saw the highest number of new drug applications approved by FDA since 1996, but John LaMattina argues that the year was even more successful than that.

Jan 8, 2015, 09:00 AM by Michael Croft

New York Times | Researchers yesterday announced a new antibiotic found in dirt. Teixobactin has not been tested in humans, but was extremely effective in animal tests.

Jan 8, 2015, 00:00 AM by Michael Croft

DUBLIN, IRELAND - Jan 8, 2015 - CLIRINX Ltd. announced today that it has launched a new web-based platform for clinical research. The software allows researchers manage their studies and collect medical research data using a sophisticated, web-based system

Jan 7, 2015, 14:30 PM by Michael Croft

Bio-IT World | Novartis today became the first big pharma company to announce a CRISPR program, through a deal with Intellia Therapeutics and Caribou Biosciences that will cover CAR-T therapies and hematopoietic stem cell programs.

Jan 7, 2015, 11:15 AM by Michael Croft

Bio-IT World | The $1,000 genome, CRISPR gene therapies, nanopore sequencing, the fall of 23andMe's health service... we look back at six of our most popular stories of 2014, and reflect on how each has developed since.

Jan 7, 2015, 09:00 AM by Michael Croft

Bio-IT World Roundup | Moderna Therapeutics closed a massive private investment round earlier this week, raising $450 million bringing their total funding to $950 million.

Jan 6, 2015, 13:50 PM by Michael Croft

Forbes | 23andMe has signed a deal with Genentech to sequence the whole genomes of 3,000 Parkinson's patients and relatives in its customer community, sharing both genetic and clinical data with the big biotech.

Jan 6, 2015, 10:00 AM by Michael Croft

Bio-IT World | David Mittelman, co-founder of Arpeggi and GCAT, the Genomics Comparison and Analytic Testing (GCAT) platform, has joined Tute Genomics as CSO.

Jan 6, 2015, 00:00 AM by Michael Croft

COLUMBIA AND BETHESDA, MD - Jan 6, 2015 - Columbia, MD and  Bethesda, MD - January 6, 2015 -  TEMIS, the leading provider of Semantic Content Enrichment solutions for the Enterprise, today announced an extension of their collaboration with the American Society for Cell Biology (ASCB) to further hone the ASCB Science Navigator, a bespoke version of TEMIS Luxid® Navigator - Biopharma Edition, as a tool for biomedical research

Jan 5, 2015, 10:55 AM by Michael Croft

FierceBiotech | Spark Therapeutics, a company with a strong Phase III drug candidate bidding to be the first gene therapy approved for use in the U.S., has filed for an IPO, planning to sell $86 million in public shares.

Jan 5, 2015, 10:30 AM by Michael Croft

Reuters | In advance of a final decision to be handed down January 7, the FDA today revealed that staff reviewers have recommended approval of a biologic made by Novartis that imitates Amgen's off-patent Neupogen.